Result of AGM

RNS Number : 2682X

Nuformix PLC

25 August 2022

 

Nuformix plc

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing,  announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved on a show of hands at the meeting.  The results of the proxy voting position received in advance of the meeting are reported below:

	Resolution	Ordinary/ Special	For		Against		Total votes cast
			No. of votes	%	No. of votes	%
1	To receive the annual report and accounts for the year ended 31 March 2022	Ordinary	150,018,268	100	0	0	150,018,268
2	To approve the Remuneration Policy	Ordinary	149,469,749	99.86	217,007	0.14	149,686,756
3	To re-appoint Julian Gilbert as a director	Ordinary	150,096,308	99.93	106,121	0.07	150,202,429
4	To re-appoint s Madeleine Kennedy as a director	Ordinary	150,096,308	99.93	106,121	0.07	150,202,429
5	To re-appoint Jeffreys Henry Audit Limited as auditor	Ordinary	150,096,308	99.93	106,121	0.07	150,202,429
6	To authorise the Directors to determine the auditor's fees.	Ordinary	149,295,087	99.40	907,342	0.60	150,202,429
7	To authorise the Directors to allot shares.	Ordinary	146,859,280	97.78	3,331,149	2.22	150,190,429
8	To authorise the Directors to disapply pre-emption rights.	Special	146,905,107	97.81	3,285,322	2.19	150,190,429
9	To authorise the Company to purchase its own shares.	Special	150,139,861	99.93	112,568	0.07	150,252,429
10	To authorise calling of a general meeting on 14 clear days' notice.	Special	150,102,429	99.93	100,000	0.07	150,202,429

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 709,309,368 ordinary shares of £0.001 each.

Enquiries:

Nuformix plc
Dr Daniel Gooding, Executive Director Dr Julian Gilbert, Non-executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
John Howes (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit  www.nuformix.com .

 

END

 

 

RAGXELFLLVLXBBV